全文获取类型
收费全文 | 4703篇 |
免费 | 507篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 138篇 |
妇产科学 | 54篇 |
基础医学 | 437篇 |
口腔科学 | 135篇 |
临床医学 | 659篇 |
内科学 | 1243篇 |
皮肤病学 | 67篇 |
神经病学 | 260篇 |
特种医学 | 494篇 |
外科学 | 564篇 |
综合类 | 65篇 |
一般理论 | 2篇 |
预防医学 | 522篇 |
眼科学 | 71篇 |
药学 | 241篇 |
肿瘤学 | 259篇 |
出版年
2023年 | 62篇 |
2022年 | 32篇 |
2021年 | 64篇 |
2020年 | 56篇 |
2019年 | 51篇 |
2018年 | 88篇 |
2017年 | 55篇 |
2016年 | 67篇 |
2015年 | 82篇 |
2014年 | 201篇 |
2013年 | 230篇 |
2012年 | 169篇 |
2011年 | 181篇 |
2010年 | 125篇 |
2009年 | 135篇 |
2008年 | 156篇 |
2007年 | 197篇 |
2006年 | 163篇 |
2005年 | 176篇 |
2004年 | 175篇 |
2003年 | 121篇 |
2002年 | 134篇 |
2001年 | 125篇 |
2000年 | 131篇 |
1999年 | 112篇 |
1998年 | 98篇 |
1997年 | 120篇 |
1996年 | 108篇 |
1995年 | 88篇 |
1994年 | 81篇 |
1993年 | 67篇 |
1992年 | 85篇 |
1991年 | 90篇 |
1990年 | 102篇 |
1989年 | 135篇 |
1988年 | 121篇 |
1987年 | 93篇 |
1986年 | 93篇 |
1985年 | 86篇 |
1984年 | 54篇 |
1983年 | 51篇 |
1982年 | 53篇 |
1981年 | 48篇 |
1980年 | 46篇 |
1979年 | 74篇 |
1978年 | 46篇 |
1977年 | 49篇 |
1976年 | 38篇 |
1974年 | 37篇 |
1973年 | 35篇 |
排序方式: 共有5234条查询结果,搜索用时 15 毫秒
71.
72.
Domenico G. Della Rocca MD Michele Magnocavallo MD Veronica N. Natale MPH Carola Gianni MD PhD Sanghamitra Mohanty MD Chintan Trivedi MD MPH Carlo Lavalle MD Giovanni B. Forleo MD PhD Nicola Tarantino MD Jorge Romero MD Xiadong Zhang MD Mohamed Bassiouny MD Amin Al-Ahmad MD David J. Burkhardt MD Joseph G. Gallinghouse MD Javier E. Sanchez MD Rodney P. Horton MD Luigi Di Biase MD PhD Andrea Natale MD 《Journal of cardiovascular electrophysiology》2021,32(9):2441-2450
73.
74.
Powles R Sirohi B Kulkarni S Treleaven J Rudin C Sankpal S Goyal S Horton C Millar B Saso R Singhal S Mehta J 《Bone marrow transplantation》2002,30(8):479-484
We have shown that primary therapy with non-myeloablative (140 mg/m(2)) high-dose melphalan (HDM) without hematopoietic support results in high response rates in untreated myeloma and very long-term survival of some patients. This study was designed to see if sufficient CD34 (+) cells can be harvested at presentation in newly diagnosed patients to administer myeloablative HDM (200 mg/m(2); HDM200) with autograft as primary therapy. This may improve outcome by rapid achievement of complete remission (CR) and possible avoidance of late myelodysplasia as a consequence of non-transplant induction chemotherapy. Thirty untreated patients received 1 g/m(2) methylprednisolone daily (days 1-6) and 12-16 micro g/kg G-CSF daily (days 3-6), and underwent leukapheresis on days 6 and 7. The median CD34(+) cell yield was 1.31 x10(6)/kg (range, 0.23-5.63), and was > or =1 x10(6)/kg in 73%. Cell yields were significantly lower than in 82 historical controls apheresed after completion of induction chemotherapy (median 2.16 x 10(6)/kg), and improved in patients who were apheresed again after induction chemotherapy. Three patients received primary therapy with HDM200 and autograft using these cells and attained CR. We conclude that it is possible to harvest stem cells in three-quarters of untreated myeloma patients. Increasing the number of apheresis procedures is needed to improve the number of CD34(+) cells collected. 相似文献
75.
Kulkarni S Powles RL Treleaven JG Singhal S Saso R Horton C Killick S Tait D Ramiah V Mehta J 《Bone marrow transplantation》1999,23(7):675-680
We describe a single centre experience of 33 patients allografted for multiple myeloma, of which 28 received matched sibling marrow, one haploidentical family donor marrow and four matched but unrelated donor marrow. Median follow-up after transplant is 27 months, and 13 patients are currently alive. One out of four patients with an unrelated donor survives and 12 out of 28 (42.8%) with matched sibling donors. Four patients were unevaluable because of early death (相似文献
76.
Brandon P. Verdoorn MD Tamara K. Evans BS Gregory J. Hanson MD Yi Zhu PhD Larissa G. P. Langhi Prata PhD Robert J. Pignolo MD PhD Elizabeth J. Atkinson MS Erin O. Wissler-Gerdes MA George A. Kuchel MD Joan B. Mannick MD Stephen B. Kritchevsky PhD Sundeep Khosla MD Stacey A. Rizza MD Jeremy D. Walston MD Nicolas Musi MD Lewis A. Lipsitz MD Douglas P. Kiel MD Raymond Yung MB ChB Nathan K. LeBrasseur PhD Ravinder J. Singh PhD Teresa McCarthy MD MS Michael A. Puskarich MD Laura J. Niedernhofer MD PhD Paul D. Robbins PhD Matthew Sorenson JD MA Tamara Tchkonia PhD James L. Kirkland MD PhD 《Journal of the American Geriatrics Society》2021,69(11):3023-3033
The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS-CoV-2 infection. SARS-CoV-2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence-associated secretory phenotype (SASP). The SASP can be amplified by infection-related pathogen-associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS-CoV-2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long-term care settings in the SARS-CoV-2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials. 相似文献
77.
Kahli Zietlow MD Leslie Dubin MSW Alethia Battles JD MSW Caroline Vitale MD 《Journal of the American Geriatrics Society》2022,70(11):3070-3079
Guardianship may pose an ethical dilemma for physicians, who must balance protecting vulnerable patients from potential safety concerns with respecting their autonomy. Older adults with dementia are particularly susceptible to loss of independence and the ability to participate in medical decision making. To have the capacity for medical decision making, individuals must understand relevant information, appreciate their circumstances, demonstrate reasoning, and express a consistent choice free from coercion. Although capacity assessments are usually task-specific, geriatricians and other specialists may be asked to comment on capacity more globally. These determinations may be used to support a Petition for the Appointment of a Guardian of a Legally Incapacitated Adult, the legal process of pursuing guardianship in probate court. Assigned guardians may be known to the incapacitated individual (e.g., a family member or friend) or may be professional guardians with no prior relationship to the ward. Guardians are encouraged to use substituted decision-making, taking into account the ward's previously expressed values and preferences. Although a number of viable alternatives to guardianship exist, numerous systemic barriers may prevent these from being fully explored. The ongoing need for guardianship should be periodically revisited and reassessed. Data about guardians and wards is shockingly sparse, as there are no centralized databases. Laws and regulations for guardianships vary significantly between states. Physicians can serve as important allies and advocates for patients with cognitive impairment at risk of incapacity, can help preserve their autonomy for as long as possible, and ensure appropriate protections are in place if the patient does lose their decision-making ability. 相似文献
78.
Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission - long-term follow-up 总被引:2,自引:0,他引:2
Vaidya SJ Atra A Bahl S Pinkerton CR Calvagna V Horton C Milan S Shepherd V Brain C Treleaven J Powles R Tait D Meller ST 《Bone marrow transplantation》2000,25(6):599-603
From 1984 to 1996, 31 consecutive children without sibling donors, aged 5-19 years (median 8) with acute lymphoblastic leukaemia (ALL) in second complete remission (CR), received unpurged autologous bone marrow transplantation (ABMT) after melphalan and single fraction total body irradiation (TBI). ABMT was performed using fresh unmanipulated marrow harvested after standard reinduction and consolidation therapy 2-11 months (median 5) after relapse. With a median survival of 2.9 years the probability of survival for all patients in continuing second CR was 45.1% (95% CI, 24%-62%) after 5 years. Regimen-related and non-leukaemia mortality was 7% (95% CI, 2%-26%). The longest time to second relapse from ABMT was 3.1 years. Pituitary and gonadal dysfunction requiring hormonal replacement therapy occurred in the majority of long-term survivors. Twelve patients developed cataracts. ABMT with melphalan/single fraction TBI has proved an effective anti-leukaemia treatment with low regimen-related mortality but significant long-term morbidity. The current approach of allogeneic BMT from an unrelated donor when no sibling donor is available, following conditioning with cyclophosphamide/ fractionated TBI has resulted in a reduced relapse rate and improved short-term overall survival in the treatment of relapsed childhood ALL. However, long-term results are awaited. 相似文献
79.
80.